BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The T-cell engager (TCE) field has seen unprecedented growth\,
  with eight approvals in the past two years—most recently tarlatamab—rein
 forcing its potential as a dominant force in immuno-oncology. Expanding a
 pplications in autoimmune diseases and a surge in business development\, 
 including Merck and Co.’s acquisition of Harpoon Therapeutics and GSK’s $
 550M agreement with Chimagen\, highlight the industry’s commitment to adv
 ancing this modality.\n\nThe 7th T-Cell Engager Therapeutics Summit remai
 ns the only event exclusively focused on translating TCEs and immune cell
  engagers from discovery to the clinic and regulatory approval. This year
 ’s program will showcase innovations to improve efficacy and safety in so
 lid tumors while exploring new opportunities in autoimmune indications.\n
 \nDespite recent successes\, challenges persist—identifying novel tumor t
 argets\, enhancing durability\, reducing on-target\, off-tumor toxicity\,
  and optimizing dosing for first-in-human studies. This summit will provi
 de the critical insights needed to overcome these hurdles and accelerate 
 clinical success.\n\nJoin C-suite executives\, biotech leaders\, and phar
 ma experts as they shape the future of T-cell engagers. With increasing m
 omentum and investment\, now is the time to stay ahead of the latest brea
 kthroughs driving the next wave of immune therapy innovation.\n\n&nbsp\;\
 n\nTime: 8:30 AM - 4:20 PM\n
DTEND:20250626T162000
DTSTAMP:20260512T230918Z
DTSTART:20250624T083000
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom Street\, Boston\, Massachu
 setts\, 02114\,
SEQUENCE:0
SUMMARY:The T-cell engager (TCE) field has seen unprecedented growth\, wit
 h eight approvals in the past two years—most recently tarlatamab—reinforc
 ing its p...
UID:443f5b4e-b75d-4f3c-80c6-f652a8b10a3b
END:VEVENT
END:VCALENDAR